Related references
Note: Only part of the references are listed.A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes
E. G. Stefanich et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Tumor Necrosis Factor-α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice Pharmacology
Thomas W. Lee et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2010)
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis
Chen S. Tan et al.
LANCET NEUROLOGY (2010)
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies
M. Allez et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody
N. Pullen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
M1647 An Orally Active Alpha4 Integrin Antagonist AJM300 Prevents the Development of Experimental Colitis Induced By Adoptive Transfer of IL-10 Deficient CD4+ T Cells in Mice
Toshihiko Sugiura et al.
GASTROENTEROLOGY (2009)
S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease — A Randomized, Double-Blind, Placebo-Controlled Trial
Masakazu Takazoe et al.
GASTROENTEROLOGY (2009)
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-alpha(4)beta(7) Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Dulce Soler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab
Maria del Pilar Martin et al.
ARCHIVES OF NEUROLOGY (2008)
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans
Fabian Zohren et al.
BLOOD (2008)
Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab
Halvard Bonig et al.
BLOOD (2008)
Integrin αE(CD103)β7 influences cellular shape and motility in a ligand-dependent fashion
Stephanie Schlickum et al.
BLOOD (2008)
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Brian G. Feagan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Homing imprinting and immunomodulation in the gut: Role of dendritic cells and retinoids
J. Rodrigo Mora
INFLAMMATORY BOWEL DISEASES (2008)
Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans
Elin Jaensson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Gastroenterology 1 - Inflammatory bowel disease: cause and immunobiology
Daniel C. Baumgart et al.
LANCET (2007)
Gastroenterology 2 - Inflammatory bowel disease: clinical aspects and established and evolving therapies
Daniel C. Baumgart et al.
LANCET (2007)
Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
Stephan R. Targan et al.
GASTROENTEROLOGY (2007)
Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis
Jesus Rivera-Nieves et al.
GASTROENTEROLOGY (2006)
A Phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis
SJH Van Deventer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial
PB Miner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis
PB Miner
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
TA Yousry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Mechanisms of disease - The many roles of chemokines and chemokine receptors in inflammation
IF Charo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The role of heparan sulphate in inflammation
Christopher R. Parish
NATURE REVIEWS IMMUNOLOGY (2006)
Tissue-tropic effector T cells: generation and targeting opportunities
William W. Agace
NATURE REVIEWS IMMUNOLOGY (2006)
Therapeutic anti-integrin (α4 and αL) monoclonal antibodies:: two-edged swords?
R González-Amaro et al.
IMMUNOLOGY (2005)
Essential role for CD103 in the T cell-mediated regulation of experimental colitis
O Annacker et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Lymphocyte homing to the gut: attraction, adhesion, and commitment
M Salmi et al.
IMMUNOLOGICAL REVIEWS (2005)
Brief report - Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
BK Kleinschmidt-DeMasters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Brief report - Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
A Langer-Gould et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin
BG Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Lymphocyte homing in the pathogenesis of extra-intestinal manifestations of inflammatory bowel disease
B Eksteen et al.
CLINICAL MEDICINE (2004)
Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease
TS Olson et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Chemokines in innate and adaptive host defense: Basic chemokinese grammar for immune cells
A Rot et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Therapeutic antagonists and conformational regulation of integrin function
M Shimaoka et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Cell-cell interactions: leukocyte-endothelial interactions
TM McIntyre et al.
CURRENT OPINION IN HEMATOLOGY (2003)
Natalizumab for active Crohn's disease.
S Ghosh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Integrins: Bidirectional, allosteric signaling machines
RO Hynes
CELL (2002)
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease
BR Yacyshyn et al.
GUT (2002)
A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin
FH Gordon et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Function and interactions of integrins
A van der Flier et al.
CELL AND TISSUE RESEARCH (2001)
A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease
FH Gordon et al.
GASTROENTEROLOGY (2001)
Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2001)
Advances in immunology: T-cell function and migration - Two sides of the same coin
UH von Andrian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice
A Soriano et al.
LABORATORY INVESTIGATION (2000)
Cutting edge: A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues
JL Pan et al.
JOURNAL OF IMMUNOLOGY (2000)
Ligand binding to integrins
EF Plow et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Advances in immunology: The immune system - Second of two parts.
PJ Delves et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
The immune system - First of two parts
PJ Delves et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Chemokines: A new classification system and their role in immunity
A Zlotnik et al.
IMMUNITY (2000)
Share Paper
